Presentation is loading. Please wait.

Presentation is loading. Please wait.

Prasugrel Background and PRINCIPLE – TIMI 44 Stephen D. Wiviott, MD Cardiovascular Division Brigham and Women’s Hospital Assistant Professor of Medicine.

Published byEdmund McKinney Modified over 9 years ago

Similar presentations

Presentation on theme: "Prasugrel Background and PRINCIPLE – TIMI 44 Stephen D. Wiviott, MD Cardiovascular Division Brigham and Women’s Hospital Assistant Professor of Medicine."— Presentation transcript:

1 Prasugrel Background and PRINCIPLE – TIMI 44 Stephen D. Wiviott, MD Cardiovascular Division Brigham and Women’s Hospital Assistant Professor of Medicine Harvard Medical School Investigator, TIMI Study Group

2 Adhesion 1 Platelets Lipid core Collagen GP la/lla bind von Willebrand Factor/GP lb bind Activation 2 Thrombin ADP 5 HT TXA 2 Aggregation 3 Fibrinogen Activated GP llb/llla Handin RI. Harrison’s Principles of Internal Medicine. Vol 1. 14th ed. NY, NY: McGraw-Hill; 1998:339. Schafer AI. Am J Med. 1996;101:199-209. Platelet Cascade in Thrombus Formation

3 Inhibition of Platelet Purinergic Receptors Storey F, et al. Platelets. 2001;12:197. Receptorsubtype Molecularstructure Secondarymessengersystem Functionalresponse P2Y 12 Inhibitor P2X 1 P2Y 1 P2Y 12 P2X 1 P2Y 1 P2Y 12 G proteinG protein Intrinsic ion GPCR GPCR channel G q G i ↓ ↓↓ ↑[Na + /Ca 2+ ] i ↑PLC/IP 3 ↓AC ↑[Ca 2+ ] i ↓[cAMP] ↑[Ca 2+ ] i ↓[cAMP] ↓↓↓ Shape change Shape change Sustained aggregation transient aggregation aggregation aggregation transient aggregation aggregation secretion secretion

4 Clopidogrel Across Spectrum of CAD COMMIT † (CCS-2) CAPRIE § Lancet 1996 MI/S troke/PAD High-Risk Vascular Disease STEMI Acute STEMI Long-term 2 o (1º) prevention UA/NSTEMI PCI UA/NSTEMI + Benefit 1 Year + Benefit 1-3 Years 30 Days + Benefit CLARITY * CURE † CREDO † CHARISMA † *Clopidogrel vs. placebo. † Clopidogrel + ASA. § Clopidogrel vs. ASA. CLARITY  20%CV death/MI/ re-isch COMMIT  9%death/MI/stroke  18.4%CV death/MI/ stroke  26.9% death/MI/ stroke  8.7% risk reduction death/MI/ stroke  7%CV death/MI/ stroke PCI Up to 3.5 years Benefit in symptomatic patients only

5 The First Clopidogrel Resistance Study (300 mg): A “Fingerprint” of Clopidogrel Response Variability Gurbel PA et al. Circulation. 2003;107:2908-2913. 2 Hours 5 Days  Aggregation (%) Resistance = 63% Resistance = 31% Resistance Resistance = 31% Resistance Resistance = 15%  Aggregation (%) Resistance Patients (%) 12 24 ≤ -30 (-30,-20] (-20,-10] (-10,0] (0,10] (10,20] (20,30] (30,40] (40,50] (50,60] >60 Patients (%) 11 22 ≤ -10(-10,0](0,10](10,20](20,30](30,40](40,50](50,60]>60 14 28 ≤ -30 (-30,-20] (-20,-10] (-10,0] (0,10] (10,20] (20,30] (30,40] (40,50] (50,60] >60 10 20 ≤ -30 (-30,-20] (-20,-10] (-10,0] (0,10] (10,20] (20,30] (30,40] (40,50] (50,60] >60  Aggregation (%) Resistance Patients (%) 24 Hours 30 Days

6 GP IIb/IIIa receptor expression P2Y 12 receptor (irreversible inhibition) Active metabolite Hepatic metabolism Cytochrome P450 pathway Intestinal absorption Variable absorption Drug-drug interactions Genetic polymorphisms CYP enzymes Drug-drug interactions Genetic polymorphisms P2Y 12 receptor Alternate pathways of platelet activation ↑ release of circulating ADP Higher baseline platelet reactivity Genetic polymorphisms Poor compliance Inadequate administration Potential Sites for Response Variability O’Donoghue M and Wiviott SD Circulation 2007

7 Clopidogrel Response Variability: Increase the Dose (300 mg vs. 600 mg) Gurbel PA et al. J Am Coll Cardiol. 2005;45:1392-1396. 0 3 6 9 12 15 18 21 24 27 30 33 ≤-30 (-30,-20] (-20,-10] (-10,0] (0,10] (10,20] (20,30] (30,40] (40,50] (50,60] (60,70] > 70 300 mg Clopidogrel 600 mg Clopidogrel   Aggregation (5 µM ADP-induced Aggregation) at 24 Hr Patients (%) Resistance = 28% (300 mg) Resistance = 8% (600 mg)

8 Clopidogrel Response Variability: Change the Agent? Prasugrel Pro-drug Oxidation (Cytochrome P450) HOOC * HS N O F Active Metabolite N S O F O Hydrolysis(Esterases) N S O CH 3 C O F O N S O ClO CH 3 C Clopidogrel 85% Inactive Metabolites Esterases N S O Cl O CH 3 C O N S O Cl O C Active Metabolite HOOC * HS N O Cl OCH 3 Herbert JM, Savi P. Sem Vasc Med. 2003;3:113-122.

9 Inhibition of Platelet Aggregation (IPA) at 24 Hours (Healthy Volunteers) -20.0 0.0 20.0 40.0 60.0 80.0 100.0 Inhibition of Platelet Aggregation (%) Response to Prasugrel Response to Clopidogrel Clopidogrel Responder Clopidogrel Non-responder *Responder =  25% IPA at 4 and 24 h Interpatient Variability Brandt JT et al. Am Heart J. 2007;153:66.e9-e16.

10 In Vitro Antiplatelet Effects of Active Metabolites in PRP * P < 0.05 ** P < 0.01 vs. control Ogawa, et al ESC 2005.

11 Prasugrel 60 mg 0.1 1 10 100 1000 01812624 Time in Hr Plasma Concentration (ng/ml) Clopidogrel 300 mg ISTH 2005 Payne et al, P0952 Insights into Potency : Active Metabolite Levels in Humans (Crossover Study)

12 Copyright ©2007 American Heart Association Wiviott SD et al, Circulation 2007 Copyright ©2007 American Heart Association Wiviott SD et al, Circulation 2007 PRasugrel IN Comparison to Clopidogrel for Inhibition of PLatelet Activation and AggrEgation (PRINCIPLE) – TIMI 44

13 Copyright ©2007 American Heart Association Wiviott SD et al, Circulation 2007 Copyright ©2007 American Heart Association Wiviott SD et al, Circulation 2007 Study Design Loading Phase N=201 Maintenance Phase N=100 No PCI 6h* Labs, 15d Events Coronary Angiography Post-Angiography Labs Planned Elective PCI Baseline Laboratory Measures Prasugrel 60 mg Clopidogrel 600 mg 0.5 h Post-Loading Dose Labs PCI 6h* Labs, 18-24h Labs Clopidogrel 150 mg x 14d Prasugrel 10 mg x 14d Prasugrel 10 mg x 14d Clopidogrel 150 mg x 14d 15d Clinical Events, Labs, † CROSSOVER 29d Clinical Events, Labs † Clopidogrel naïve No planned GP IIb/IIIa use 1º EPs: *Loading = 6h IPA (20 µM ADP); † Maintenance = 15d or 29d IPA (20 µM ADP) Copyright ©2007 American Heart Association Wiviott SD et al, Circulation 2007

14 PRINCIPLE – TIMI 44 14 Trial Organization US Lead and PI: S Wiviott ROW Lead: FJ Neumann US Sites (4) D. Angiolillo E. Bates M. Furman D. Purdy US Sites (4) D. Angiolillo E. Bates M. Furman D. Purdy France Lead: G. Montalescot France Lead: G. Montalescot Israel Lead: H. Hod Israel Lead: H. Hod German Lead: FJ Neumann German Lead: FJ Neumann France Sites (3) J-L Bonnet B Charbonnier E Van Belle France Sites (3) J-L Bonnet B Charbonnier E Van Belle German Sites (5) M Gawaz A Schomig R Voss B Witzenblicher FJ Neumann German Sites (5) M Gawaz A Schomig R Voss B Witzenblicher FJ Neumann Israel Sites (3) L Gruberg H Danenberg S Matetsky Israel Sites (3) L Gruberg H Danenberg S Matetsky Study Chairman: Eugene BraunwaldDirector: Carolyn McCabe

15 Copyright ©2007 American Heart Association Wiviott SD et al, Circulation 2007 Copyright ©2007 American Heart Association Wiviott SD et al, Circulation 2007 PRIMARY EP Acute Phase: IPA 20 uM ADP Prasugrel 60 mg P<0.0001 for each IPA (%; 20  M ADP) Copyright ©2007 American Heart Association Wiviott SD et al, Circulation 2007 Hours

16 Copyright ©2007 American Heart Association Wiviott SD et al, Circulation 2007 Copyright ©2007 American Heart Association Wiviott SD et al, Circulation 2007 Maximal Platelet Aggregation (MPA) Prasugrel 60 mg P<0.0001 for each MPA (%; 20  M ADP) Hours

17 Copyright ©2007 American Heart Association Wiviott SD et al, Circulation 2007 Copyright ©2007 American Heart Association Wiviott SD et al, Circulation 2007 Prasugrel 10 mg Difference Between Treatments: 14.9 [95% CI 10.6 – 19.3], P<0.0001 IPA (%; 20  M ADP) Days PRIMARY EP Chronic Phase: IPA 20 uM ADP

18 Copyright ©2007 American Heart Association Wiviott SD et al, Circulation 2007 Copyright ©2007 American Heart Association Wiviott SD et al, Circulation 2007 Maximal Platelet Aggregation (MPA) Prasugrel 10 mg Difference Between Treatments: 11.3 [95% CI 8.1 – 14.5], P<0.0001 Clopidogrel 150 mg MPA (%; 20  M ADP) Days

19 Copyright ©2007 American Heart Association Wiviott SD et al, Circulation 2007 Copyright ©2007 American Heart Association Wiviott SD et al, Circulation 2007 Thienopyridine Hyporesponsiveness: IPA 20 uM ADP < 20% P =0.06 P =0.18 P =0.0002 P =0.0005 P <0.0001 P =0.0008 Clopidogrel Prasugrel Hours Percent of Subjects

20 Copyright ©2007 American Heart Association Wiviott SD et al, Circulation 2007Implications PRINCIPLE – TIMI 44 extends the pharmacologic superiority of the TRITON – TIMI 38 dose of prasugrel (60 mg/10 mg) to higher doses of clopidogrel (600 mg/150mg) in PCI. TRITON – TIMI 38 1 tested hypothesis that an agent with higher and more consistent IPA than standard approved clopidogrel (300 mg/ 75 mg) will improve clinical outcomes 1 Wiviott SD, Braunwald E, McCabe CH et al NEJM2007

Download ppt "Prasugrel Background and PRINCIPLE – TIMI 44 Stephen D. Wiviott, MD Cardiovascular Division Brigham and Women’s Hospital Assistant Professor of Medicine."

Similar presentations

Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines INTERACTION BETWEEN CLOPIDROGEL AND PROTON PUMP INHIBITORS Working.

Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines INTERACTION BETWEEN CLOPIDROGEL AND PROTON PUMP INHIBITORS Working.
Canadian Diabetes Association Clinical Practice Guidelines Acute Coronary Syndromes and Diabetes Chapter 26 Jean-Claude Tardif, Phillipe L. L’Allier, David.

Canadian Diabetes Association Clinical Practice Guidelines Acute Coronary Syndromes and Diabetes Chapter 26 Jean-Claude Tardif, Phillipe L. L’Allier, David.
Inhibitory Effects of Ticagrelor Compared to Clopidogrel on Platelet Function in Patients with Acute Coronary Syndromes The PLATO PLATELET Substudy Storey.

Inhibitory Effects of Ticagrelor Compared to Clopidogrel on Platelet Function in Patients with Acute Coronary Syndromes The PLATO PLATELET Substudy Storey.
Thrombus Susceptibility and the Vulnerable Plaque Relationship Between Inflammation and Thrombosis.

Thrombus Susceptibility and the Vulnerable Plaque Relationship Between Inflammation and Thrombosis.
North of Tyne anti-platelet guidelines: use in primary care Jane S Skinner Consultant Community Cardiologist.

North of Tyne anti-platelet guidelines: use in primary care Jane S Skinner Consultant Community Cardiologist.
Oral Antiplatelet Agents: A Cornerstone of Therapy for Atherothrombotic Disease Aspirin and clopidogrel: - Reduce the risks of myocardial infarction, ischemic.

Oral Antiplatelet Agents: A Cornerstone of Therapy for Atherothrombotic Disease Aspirin and clopidogrel: - Reduce the risks of myocardial infarction, ischemic.
Prasugrel vs ticagrelor in acute coronary syndromes

Prasugrel vs ticagrelor in acute coronary syndromes
Hepatic generation of active metabolite Pharmacogenetics of Cardiovascular Antithrombotic Therapy CYP = cytochrome P450. GP = glycoprotein. MDR = multidrug.

Hepatic generation of active metabolite Pharmacogenetics of Cardiovascular Antithrombotic Therapy CYP = cytochrome P450. GP = glycoprotein. MDR = multidrug.
Pharmacology in Acute Coronary Syndromes: Anti-platelet Agents Tim Kinnaird, University Hospital Wales, Cardiff and Vale NHS Trust.

Pharmacology in Acute Coronary Syndromes: Anti-platelet Agents Tim Kinnaird, University Hospital Wales, Cardiff and Vale NHS Trust.
Novel antithrombotic agents in acute coronary syndromes: better or worse than P2Y12 inhibitors Giuseppe Biondi Zoccai Sapienza Università di Roma

Novel antithrombotic agents in acute coronary syndromes: better or worse than P2Y12 inhibitors Giuseppe Biondi Zoccai Sapienza Università di Roma
TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel TRITON-TIMI 38 TRITON-TIMI 38 Elliott M. Antman, MD.

TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel TRITON-TIMI 38 TRITON-TIMI 38 Elliott M. Antman, MD.
Prasugrel Compared to Clopidogrel in Patients with Acute Coronary Syndromes Undergoing PCI with Stenting: the TRITON - TIMI 38 Stent Analysis Stephen D.

Prasugrel Compared to Clopidogrel in Patients with Acute Coronary Syndromes Undergoing PCI with Stenting: the TRITON - TIMI 38 Stent Analysis Stephen D.
Prasugrel Compared to Clopidogrel in Patients with Acute Coronary Syndromes Undergoing PCI with Stenting: the TRITON - TIMI 38 Stent Analysis Stephen D.

Prasugrel Compared to Clopidogrel in Patients with Acute Coronary Syndromes Undergoing PCI with Stenting: the TRITON - TIMI 38 Stent Analysis Stephen D.
Clopidogrel in ACS: Overview Investigator, TIMI Study Group Associate Physician, Cardiovascular Division, BWH Assistant Professor of Medicine, Harvard.

Clopidogrel in ACS: Overview Investigator, TIMI Study Group Associate Physician, Cardiovascular Division, BWH Assistant Professor of Medicine, Harvard.
ADP Receptors Bhatt DL et al. Nature Reviews Drug Discovery 2003; 2:15-28.

ADP Receptors Bhatt DL et al. Nature Reviews Drug Discovery 2003; 2:15-28.
Perspective on COMMIT/CCS-2 Trial of Clopidogrel in STEMI Christopher Cannon, M.D. Brigham and Women’s Hospital Boston, MA.

Perspective on COMMIT/CCS-2 Trial of Clopidogrel in STEMI Christopher Cannon, M.D. Brigham and Women’s Hospital Boston, MA.
Point of Care Platelet Function Testing – Is There Still Value?

Point of Care Platelet Function Testing – Is There Still Value?
Ticlopidine (Ticlid™) and Clopidogrel (Plavix™) Benedict R. Lucchesi, M.D., Ph.D. Department of Pharmacology University of Michigan Medical School.

Ticlopidine (Ticlid™) and Clopidogrel (Plavix™) Benedict R. Lucchesi, M.D., Ph.D. Department of Pharmacology University of Michigan Medical School.
Introduction Clopidogrel is metabolized by P450 (CYP)-isoenzymes: CYP 3A4/5, 1A2, 2B6, 2C9, and 2C19 1 Wide response variability and nonresponsiveness.

Introduction Clopidogrel is metabolized by P450 (CYP)-isoenzymes: CYP 3A4/5, 1A2, 2B6, 2C9, and 2C19 1 Wide response variability and nonresponsiveness.
S. Banai, M.D. Loading dose with Clopidogrel before PCI How high should we go? Shmuel Banai, MD Director, Interventional Cardiology Tel Aviv Medical Center.

S. Banai, M.D. Loading dose with Clopidogrel before PCI How high should we go? Shmuel Banai, MD Director, Interventional Cardiology Tel Aviv Medical Center.

Similar presentations

Ads by Google